A meta-analysis by Pourbaix et al found a overall risk ratio of 1.41 when comparing risk of IFI in smokers to non-smokers, particularly for infections caused by dimorphic fungi such as histoplasmosis, blastomycosis and coccidioidomycosis
New prospective open-label study on anidulafungin for invasive candidiasis in children
Recommendations for using anidulafungin (Ecalta/Eraxis) to treat invasive candidiasis in children are largely extrapolated from trials in adults. Dr Roilides and colleagues have published data from a trial of 49 children reporting a global response rate of 71% and a drug-related adverse event rate of 37% (10% discontinued due to AEs).